FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes

Click here to view online. Add this email to your safelist.

28 February 2017

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.